Form 4: Regeneron EVP Murphy Receives Stock, Options Award

Regeneron Pharmaceuticals' EVP of Research, Andrew J. Murphy, reported the acquisition of restricted stock and non-qualified stock options, alongside a disposition of shares for tax withholding.

Summary

• Andrew J. Murphy, EVP Research at Regeneron Pharmaceuticals, Inc., reported transactions occurring in December 2025.
• On December 5, 2025, Murphy was awarded 3,715 shares of Common Stock as Restricted Stock under the company's Second Amended and Restated 2014 Long-Term Incentive Plan. These shares vest 50% on December 5, 2027, and 50% on December 5, 2029.
• Also on December 5, 2025, Murphy received an award of 18,315 Non-Qualified Stock Options with an exercise price of $726.71. These options vest in four equal annual installments, commencing one year after the grant date, and expire on December 5, 2035.
• On December 8, 2025, Murphy disposed of 1,699 shares of Common Stock at a price of $712.94 per share, likely for tax withholding purposes (Transaction Code 'F').
• Following these transactions, Murphy directly beneficially owns 52,062 shares of Common Stock and 18,315 derivative securities (stock options).
• Additionally, Murphy indirectly beneficially owns 4,375 shares of Common Stock through a 401(k) Plan.

Sentiment

Score: 7

Explanation: The filing reports routine executive compensation awards, which are generally positive for executive retention and alignment with shareholder interests. The disposition of shares is for tax withholding, a standard practice. No negative surprises or significant sales are indicated.

Positives

• Award of 3,715 shares of Restricted Stock, aligning executive interests with long-term shareholder value.
• Grant of 18,315 Non-Qualified Stock Options, providing incentive for future performance and potential capital appreciation.
• These awards are part of the company's established 2014 Long-Term Incentive Plan, indicating a structured approach to executive compensation.

Negatives

• Disposition of 1,699 shares of Common Stock for tax withholding, which reduces direct beneficial ownership.

Future Outlook

The vesting schedules for the restricted stock and stock options extend into 2027, 2029, and 2035, indicating a long-term incentive structure for the executive and aligning their interests with future company performance.

Industry Context

Executive compensation, particularly through equity awards like restricted stock and stock options, is a standard practice in the biotechnology and pharmaceutical industries to attract, retain, and incentivize key talent. These awards align executive interests with long-term company performance and shareholder value creation, which is crucial in an industry with long development cycles and high R&D costs.

Comparison to Industry Standards

• Equity-based compensation, including restricted stock and stock options, is a common practice for executive remuneration across the pharmaceutical and biotechnology sectors, comparable to companies like Pfizer, Merck, and Johnson & Johnson.
• The vesting schedules (2-year for restricted stock, 4-year for options) are within typical industry ranges designed to promote long-term retention and performance.
• The exercise price of the options ($726.71) reflects the market price at the time of grant, a standard practice for non-qualified stock options.

Stakeholder Impact

• Shareholders: The equity awards align the EVP's interests with long-term shareholder value creation, potentially leading to better performance. The tax-related sale is minor and not indicative of a lack of confidence.
• Employees: Standard executive compensation practices can set a precedent for broader employee incentive programs.
• Management: The awards serve as a retention and incentive mechanism for a key executive in research.

Next Steps

• Vesting of 50% of Restricted Stock on December 5, 2027.
• Vesting of the remaining 50% of Restricted Stock on December 5, 2029.
• Annual vesting of Non-Qualified Stock Options over four years, commencing December 5, 2026.
• Expiration of Non-Qualified Stock Options on December 5, 2035.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation awards and a tax-related disposition. It does not provide new information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The awards are a standard part of executive incentive programs, aligning management interests with long-term shareholder value. Investors should continue to hold based on broader company fundamentals and market conditions, as this filing offers no specific catalysts for a 'buy' or 'sell' decision.

Keywords

Regeneron Pharmaceuticals, REGN, Andrew J. Murphy, SEC Form 4, Insider Trading, Stock Award, Restricted Stock, Stock Options, Executive Compensation, Long-Term Incentive Plan, Biotechnology, Pharmaceuticals